Cognitive & Mood AnticholinergicFDA-approved medicinePrescription drug

Scopolamine Patch

Transderm Scop · Scopoderm · Scopolamine TTS

Evidence: Approved label. Example dose: finalize with a provider. Not a fact-check stamp.

1 mg over 3 days (one 1.5 mg patch) – 1 mg (patch) Topical Every 3 days (72 hours)

AntiemeticMuscarinic receptor antagonistReservoir transdermal

Transderm-Scop (scopolamine patch) is a 3-day transdermal delivery system containing 1.5 mg scopolamine, releasing approximately 1 mg over 72 hours. Applied behind the ear on hairless skin, it is used primarily for prevention of motion sickness and post-operative nausea and vomiting. IMPORTANT: This is a RESERVOIR-type patch with a rate-controlling membrane - it must NEVER be cut, as cutting destroys the membrane and causes dose dump. Patch must be removed before MRI due to its metal backing.

Quick Start

Route

Transdermal Patch

Start low

1 mg Topical

Frequency

Every 3 days (72 hours)

Timing

Anytime

Starting dose. 1 mg — Over 3 days (one 1.5 mg patch)

Apply behind one ear on hairless skin 4 hours before needed effect. Wash hands thoroughly after application to avoid eye contact (causes pupil dilation in the exposed eye).

❋

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first

Conservative start

1 mg over 3 days (one 1.5 mg patch) · Transdermal Patch · Every 3 days (72 hours)

conservative starter

1 mg over 3 days (one 1.5 mg patch)

Every 3 days (72 hours)

Standard

Motion Sickness Prophylaxis

1 mg (patch) · Topical · As needed

human clinical trial · FDA Transderm Scop label

Patch slowly releases 1mg over 72 hours. Apply to a hairless area behind the ear.

1 mg (patch)

As needed

◆

How it works

Scopolamine is a non-selective muscarinic acetylcholine receptor (mAChR) antagonist with activity at M1 receptors in the vestibular nuclei and vomiting center. By blocking cholinergic signaling in these central pathways, it dampens the nausea response to vestibular stimulation (motion) and interrupts afferent emetic signaling postoperatively. Its tertiary-amine structure allows it to cross the blood-brain barrier, giving it stronger central antiemetic effects than peripheral anticholinergics.

What to expect

Early

Days 1–7

0-4 hours: onset of effect

Evidence

HumanPresent

AnimalPresent

In-vitroPresent

Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.

The alkaloid L-(-)-scopolamine [L-(-)-hyoscine] competitively inhibits muscarinic receptors for acetylcholine and acts as a nonselective muscarinic antagonist, producing both peripheral antimuscarinic properties and central sedative, antiemetic, and amnestic effects.

The alkaloid L-(-)-scopolamine [L-(-)-hyoscine] competitively inhibits muscarinic receptors for acetylcholine and acts as a nonselective muscarinic antagonist, producing both peripheral antimuscarinic properties and central sedative, antiemetic, and amnestic effects.

Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. Therapeutic drug monitoring · 2005 · PMID 16175141

Evidence scope. Clinical pharmacology review; mechanism supports scopolamine generally but not the exact patch release schedule.

Claims we could not support

No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.

Dose/route: 1 mg over 3 days (one 1.5 mg patch) via Transdermal Patch, Every 3 days (72 hours). No checked live PubMed abstract supported this complete molecule/formulation/route/dose/frequency combination.

Primary safety claim: Dry mouth (60-70%). No checked live abstract directly established this as the primary concern for the card's exact formulation and regimen.

Interactions & stacking

Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.

Documented together

Ondansetron (5-HT3 antagonist)Different mechanism - additive antiemetic effect in PONV.

Keep separate

Anticholinergic medications (antihistamines, TCAs, bladder antispasmodics)Additive anticholinergic burden - confusion, urinary retention, tachycardia. Especially risky in elderly users.

MAOIsTheoretical anticholinergic crisis. Avoid combination.

Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.

Side effects & safety

Commonly reported

Dry mouth (60-70%)
Blurred vision (mydriasis in exposed eye)
Drowsiness
Urinary retention

Less common & notes

Confusion (especially in elderly)
Hallucinations
Heat intolerance
Constipation

Pharmacokinetics

Illustrative plasma concentration · 41 h

Half-life

~10 hours

After patch removal

Peak · Tmax

Onset ~4 hours; full effect by 8 hours

Elimination

~24 hours

After patch removal for full washout

Bioavailability

~50-100%

Transdermal

Duration of action

72 hours

Per patch (every 3 days)

Clearance

Hepatic hydrolysis; renal excretion

Storage. Store pouched patches at room temperature (20-25C). Apply immediately upon opening. Aluminized backing means patch must be removed before MRI.

Regulatory status

FDA-approved for motion sickness and PONV. Prescription-only. Classified as anticholinergic - avoid in narrow-angle glaucoma, urinary retention, pyloric stenosis.

Put it to work

Calculate, log & track

Open Scopolamine Patch straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Scopolamine Patch in the app →

Go deeper

The guide & community

The complete Scopolamine Patch walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗

Open in app Community